23andMe SPAC Presentation Deck

Cumulative Genotyped Customers (in M, fiscal year ends March 31) 2.0 We Are Redefining Healthcare. With Data. At Scale. FY17A 4.4 FY18A 10M+ Genetic Profiles Created Critical Mass¹ 7.8 FY19A 9.8 FY20A 11.2 FY21E 12.6 FY22E 14.3 FY23E 16.4 FY24E 18.5M consented customers allows 23andMe to perform Genome-Wide Association Studies with over 10,000 cases on all diseases over 0.1% prevalence. 2 Based on internal estimates subject to scientific, development and compliance risks. Includes collaborated, 100% owned and royalty interests targets. Empowering Consumers 10.7M Genotyped Customers Enabling Research & Services 4B+ Phenotypic Data Points Developing Therapeutics 30+ Programs² 23and Me Confidential and Proprietary Information 10

View entire presentation